BROWSE·page 698 of 710

Browse EX-10 agreements

8,509 total material contract exhibits.


EX-10.3

EX-10.3

MKS INC.

Restricted Stock Unit Agreement

Granted Under the 2022 Stock Incentive Plan (as amended and restated)

AGREEMENT made ____________ (the “Grant Date”), between MKS Inc., a Massachusettscorporation (the “Company”), and ____________(the “Participant”).

For valuable consideration, receipt of which is acknowledged, the parties hereto agree as follows:

  1. General. The Company hereby grants to the Participant restricted stock units (“RSUs”) with respect to the number of shares set forth in Exhibit A hereto (the “Shares”) of common stock, no par value, of the Company (“Common Stock”), subject to the terms and conditions set forth in this Agreement and in the Company’s 2022 Stock Incentive Plan (as amended and restated effective May 11, 2026, the “Plan”). The RSUs represent a promise by the Company to deliver Shares upon vesting and settlement.

(a) Definitions. Capitalized terms not explicitly defined in this Agreement shall have the same meanings given to them in the Plan.

(i) “Code” means the U.S. Internal Revenue Code of 1986, as amended.

EX-10.3·8-K·CIK 1049502·ACC 0001193125-26-219474·Filed May 13, 2026, 07:58 EDT

EX-10.2

EX-10.2

MKS INC.

Restricted Stock Unit Agreement for Non-Employee Directors

Granted Under the 2022 Stock Incentive Plan (as amended and restated)

AGREEMENT made ____________ (the “Grant Date”), between MKS Inc., a Massachusetts corporation (the “Company”), and ____________ (the “Participant”).

For valuable consideration, receipt of which is acknowledged, the parties hereto agree as follows:

  1. General. The Company has granted to the Participant restricted stock units (“RSUs”) with respect to the number of shares set forth in Exhibit A hereto (the “Shares”) of common stock, no par value, of the Company (“Common Stock”), subject to the terms and conditions set forth in this Agreement and in the Company’s 2022 Stock Incentive Plan (as amended and restated effective May 11, 2026, the “Plan”). The RSUs represent a promise by the Company to deliver Shares upon vesting and settlement.

(a) Definitions. Capitalized terms not explicitly defined in this Agreement shall have the same meanings given to them in the Plan.

EX-10.2·8-K·CIK 1049502·ACC 0001193125-26-219474·Filed May 13, 2026, 07:58 EDT

KNOX GOLF ACADEMY, INC

CONVERTIBLE PROMISSORY NOTE

This Convertible Promissory Note (the “Note”) is issued as of May 7, 2026 by KNOX GOLF ACADEMY, INC, a duly incorporated company under the laws of New York (the “Company”), to Paranovus Entertainment Technology Ltd., a duly incorporated company under the laws of Cayman Islands (the “Investor”).

  1. PRINCIPAL AMOUNT AND DISBURSEMENT

The Investor agrees to provide a total loan facility of up to USD 1,000,000 (the “Principal Amount”), to be disbursed in two tranches:

(a) First Tranche: USD 500,000 upon execution of this Note;

(b) Second Tranche: USD 500,000, to be funded in 30 days from execution of this Note.

  1. INTEREST

The outstanding Principal Amount shall bear interest at a rate of ten percent (10%) per annum. Interest shall accrue from the date of each disbursement and shall be calculated on the basis of a 365-day year. Accrued interest shall be payable upon repayment or conversion.

  1. TERM AND MATURITY

EX-10.1·6-K·CIK 1751876·ACC 0001929980-26-000207·Filed May 13, 2026, 07:58 EDT

THIS PROMISSORY NOTE (“NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

PROMISSORY NOTE

Principal Amount: Up to $100,000 Dated as of May 6, 2026

EX-10.1·8-K·CIK 2108164·ACC 0001213900-26-055079·Filed May 13, 2026, 07:58 EDT

EX-10.1

EX-10.1

Sublease Agreement

This Sublease Agreement (the "Sublease") is made and effective April 24, 2026, by and between Atara Biotherapeutics, Inc., a Delaware corporation, having an address at 1280 Rancho Conejo Boulevard, Thousand Oaks, CA 91320 ("Sublessor"), and 20Bloc ("Subtenant"). Defined terms used but not otherwise defined herein have the meaning ascribed to them in the Lease Agreement.

RECITALS

A. Sublessor is the tenant in a Lease Agreement dated March 17, 2021, including amendments with JackieO, LLC (“Landlord”) (the "Lease Agreement"). A copy of the Lease Agreement is attached hereto as Exhibit A and incorporated herein by this reference. The property leased to Sublessor in the Lease Agreement is referred to as the "Leased Property".

B. Sublessor desires to sublease the Storage Space (A.2), with 1,001 rentable square feet as shown on the floor plan attached to this Sublease as Exhibit B (the “Sublease Premises”) to Subtenant.

EX-10.1·10-Q·CIK 1604464·ACC 0001193125-26-219482·Filed May 13, 2026, 07:58 EDT

EX-10.1

EX-10.1

AMENDMENT No. 6

AMENDMENT NO. 6, dated as of March 30, 2026 (this “Amendment”), by and among LUMEXA IMAGING, INC., a Delaware corporation (the “LII Borrower”), LUMEXA IMAGING OUTPATIENT, INC., a Delaware corporation (the “LIO Borrower” and together with the LII Borrower, the “Borrowers”) and Barclays Bank PLC, as administrative agent (in such capacity, including any successor thereto, the “Administrative Agent”).

W I T N E S S E T H

WHEREAS, pursuant to that certain Credit Agreement, dated as of December 15, 2020 (as amended or otherwise modified by Incremental Amendment No. 1, dated as of December 31, 2021, Amendment No. 2, dated as of March 21, 2023, Amendment No. 3, dated as of July 16, 2024, Amendment No. 4, dated as of November 22, 2024, Amendment No. 5, dated as of December 17, 2025 and as further amended, restated, amended and restated, supplemented or otherwise modified from time to time prior to the date hereof, the “Credit Agreement”), by and among the Borrowers, Lumexa Imaging Intermediate Holdings, Inc., a Delaware corporation, Lumexa Imaging Outpatient Intermediate Ho

EX-10.1·10-Q·CIK 2071288·ACC 0001193125-26-219480·Filed May 13, 2026, 07:58 EDT

EX-10.1

EX-10.1

CONTRIBUTION AGREEMENT

among

AMERICOLD REALTY OPERATING PARTNERSHIP, L.P.,

a Delaware limited partnership,

AMERICOLD NORTH AMERICA JV MEMBER, LLC,

a Delaware limited liability company

MHG GATEWAY PROPERTIES, LLC,

a New Jersey limited liability company,

ART MORTGAGE BORROWER PROPCO 2010 - 5 LLC,

a Delaware limited liability company,

AMERICOLD NEW TRS SUB 1, LLC,

a Delaware limited liability company,

AMERICOLD REAL ESTATE, L.P.,

a Delaware limited partnership,

ART MORTGAGE BORROWER PROPCO 2010 - 4 LLC,

a Delaware limited liability company,

NEW HALL’S WAREHOUSE LLC,

a New Jersey limited liability company,

AMERICOLD RUSSELLVILLE, LLC,

an Arkansas limited liability company,

and

SNOWFALL TOPCO LP,

a Delaware limited partnership

Effective Date: May 7, 2026


Table of Contents

EX-10.1·8-K/A·CIK 1455863·ACC 0001193125-26-219493·Filed May 13, 2026, 07:58 EDT

EX-10.11

EX-10.11

EMPLOYEE FORM

Name of Participant: [__________]
Number of Shares of Stock subject to the SAR: [__________]
Exercise Price Per Share: $[__________]
Date of Grant: [__________]
Original Grant Date [__________]

WATERS CORPORATION

2026 EQUITY BASED COMPENSATION PLAN

GLOBAL SAR AWARD AGREEMENT

This agreement (this “Agreement”) including any appendix hereto containing country-specific terms and conditions (each an “Appendix”, and collectively the “Appendices”) evidences a stock appreciation right granted by Waters Corporation (the “Company”) to the individual named above (the “Participant”), pursuant to and subject to the terms and conditions of the Waters Corporation 2026 Equity-Based Compensation Plan (as from time to time amended and in effect, the “Plan”). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.

EX-10.11·10-Q·CIK 1000697·ACC 0001193125-26-219487·Filed May 13, 2026, 07:58 EDT

EX-10.10

EX-10.10

EMPLOYEE FORM

Name of Participant: [____]
Number of Restricted Stock Units: [____]
Date of Grant: [____]
Original Grant Date [____]

WATERS CORPORATION

2026 EQUITY BASED COMPENSATION PLAN

GLOBAL RESTRICTED STOCK UNIT AWARD AGREEMENT

This agreement (this “Agreement”) including the appendices hereto containing general terms and conditions for Participants outside the United States and country-specific terms and conditions (each an “Appendix,” and collectively the “Appendices”) evidences Restricted Stock Units granted by Waters Corporation (the “Company”) to the individual named above (the “Participant”), pursuant to and subject to the terms and conditions of the Waters Corporation 2026 Equity Based Compensation Plan (as from time to time amended and in effect, the “Plan”). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.

EX-10.10·10-Q·CIK 1000697·ACC 0001193125-26-219487·Filed May 13, 2026, 07:58 EDT

[●], 2026

PERSONAL AND CONFIDENTIAL

Dr. Steve Slilaty, Chief Executive Officer

Sunshine Biopharma Inc.

333 Las Olas Way, CU4 Suite 433 Fort Lauderdale, FL 33301

Re: **SBFM

Dear Dr. Slilaty:

The purpose of this placement agent agreement is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the placement agent on a “best efforts” basis in connection with the proposed Best Efforts Secondary Offering (the “Placement”) by Sunshine Biopharma Inc. (collectively, with its subsidiaries and affiliates, the “Company”) of units consisting of its shares of Common Stock and warrants to purchase its shares of Common Stock (the “Securities”). This placement agent agreement sets forth certain conditions and assumptions upon which the Placement is premised. The Company expressly acknowledges and agrees that Aegis’s obligations hereunder are on a reasonable “best efforts” basis only and that the execution of

EX-10.22·S-1·CIK 1402328·ACC 0001683168-26-003726·Filed May 13, 2026, 07:58 EDT

SERIES C REGISTERED COMMON WARRANT TO PURCHASE COMMON STOCK

SUNSHINE BIOPHARMA INC.

Warrant Shares: [●] Initial Exercise Date: [●], 2026
Issuance Date: [●], 2026

THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Initial Exercise Date and on or prior to 5:00 p.m. (New York City time) on [●], 2031 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Sunshine Biopharma Inc., a Colorado corporation (the “Company”), up to [●] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. Subject to the provisions of Section 2.3, the purchase price of one (1) share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2.2.

EX-10.21·S-1·CIK 1402328·ACC 0001683168-26-003726·Filed May 13, 2026, 07:58 EDT

REGISTERED PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK

SUNSHINE BIOPHARMA INC.

Warrant Shares: [●] Initial Exercise Date: [●], 2026
Issuance Date: [●], 2026

THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time until this Warrant is exercised in full (the “Termination Date”), to subscribe for and purchase from Sunshine Biopharma Inc., a Colorado corporation (the “Company”), up to [●] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. Subject to the provisions of Section 2.3, the purchase price of one (1) share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2.2.

EX-10.20·S-1·CIK 1402328·ACC 0001683168-26-003726·Filed May 13, 2026, 07:58 EDT